Navigation Links
Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
Date:1/20/2008

DALLAS Jan. 21, 2008 Findings by UT Southwestern Medical Center researchers encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.

In todays online issue of Cancer, UT Southwestern doctors analyzed data gathered by the National Cancer Institutes Prostate Cancer Prevention Trial, or PCPT. The trial, which began in October 1993, was designed to test whether finasteride could prevent prostate cancer in men 55 years of age and older. It was stopped early in June 2003 when an analysis showed that finasteride reduced the risk of developing prostate cancer by 25 percent.

UT Southwesterns analysis of the PCPT data indicates that cost effectiveness and quality of life issues associated with taking the drug are not clear cut, said Dr. Yair Lotan, assistant professor of urology and the Cancer studys senior author. The PCPT data show that in addition to preventing prostate cancer, finasteride also reduces urinary-tract symptoms associated with benign prostatic hyperplasia. It also decreased sexual desire and caused impotence in 5 percent of the trial participants. Some PCPT participants who did develop prostate cancer also had high-grade tumors, although there is ongoing debate whether this result might have been due to sampling bias.

Finasteride is currently the only drug that has been shown to prevent prostate cancer in a large randomized trial but is used for this purpose in very few men, Dr. Lotan said. A large number of patients are currently taking over-the-counter supplements to prevent prostate cancer, even though there is no scientific evidence to support these products claims. Its important for patients to be aware of this scientific trial and to ask their doctors if finasteride could benefit them.

In light of all these pros and cons, Dr. Lotan said physicians and patients need to work together closely to weigh how finasteride could affect quality of life on a case-by-case basis.

With the exception of skin cancer, prostate cancer is the most common cancer in American men, Dr. Lotan said. Men who are at low risk for prostate cancer might view taking finasteride as not very cost effective when considering its impact on their quality of life. On the other hand, patients at high risk might see it as cost effective because it lessens their chances of developing prostate cancer.

Because there is some complexity to the PCPT I think doctors hesitate to discuss its results. While Im not advocating for the drug, I think physicians should mention finasteride, especially when their patients are asking questions about ways to prevent prostate cancer. Patients should understand and be aware of the proven science thats out there.


'/>"/>

Contact: Erin Prather Stafford
erin.pratherstafford@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales
2. Many Osteoporosis Medications Prevent Fractures, But None Is Proven Best
3. New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Familys Feet
4. Gildas Club Worldwide is a Proven Partner in Quality Cancer Care
5. Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
6. Smoked cannabis proven effective in treating neuropathic pain
7. Benefit of exenatide has not yet been proven
8. Proven Nutrition Provides Energy and Hope to Cancer Fighters
9. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
10. European Summit on Cardiovascular Disease Prevention
11. One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: